Relevance of NAT2 genotype and clinical factors to risk for antituberculosis drug-induced liver injury

Pharmacogenomics. 2024 Jan;25(1):21-28. doi: 10.2217/pgs-2023-0148. Epub 2023 Dec 22.

Abstract

The study analyzes the risk factors associated with antituberculosis drug-induced liver injury (ATB-DILI), and the relationship between ATB-DILI and NAT2 gene polymorphisms. Out of the 324 included patients, 57 (17.59%) developed ATB-DILI. Age, history of liver disease, alcohol consumption and timing of antituberculosis (ATB) treatment were independent risk factors for ATB-DILI in the patients with tuberculosis (TB; p < 0.05). There was a significant difference in the distribution of NAT2 metabolic phenotypes between the study group and the control group (p < 0.05). The ATB drug treatment for pulmonary TB can cause a high incidence of ATB-DILI. Age, history of liver disease, alcohol consumption and timing of ATB treatment are independent risk factors for ATB-DILI in patients with TB.

Keywords: NAT2; drug-induced liver injury; isoniazid; tuberculosis.

MeSH terms

  • Antitubercular Agents / adverse effects
  • Arylamine N-Acetyltransferase* / genetics
  • Chemical and Drug Induced Liver Injury* / epidemiology
  • Chemical and Drug Induced Liver Injury* / genetics
  • Genotype
  • Humans
  • Risk Factors
  • Tuberculosis* / complications
  • Tuberculosis* / drug therapy
  • Tuberculosis* / genetics

Substances

  • Antitubercular Agents
  • Arylamine N-Acetyltransferase
  • NAT2 protein, human